SUMMARY In previous studies adenine arabinoside and trifluorothymidine were found to be equally effective treatments for dendritic ulcers of the cornea, but a trend emerged which suggested that in amoeboid ulcers trifluorothymidine was more effective. The collection of additional cases confirms the superiority of trifluorothymidine in such cases.
Despite extensive research 5-iodo-2'-deoxyuridine (IDU) has remained until recently the only antiviral agent generally available to clinicians for treating ulcerative herpetic keratitis.
Adenine arabinoside (Ara-A) and trifluorothymidine (F3T) (Wellings et al., 1972; Pavan-Langston, 1975; Coster et al., 1976) are both highly effective in treating herpetic corneal ulceration. In a large series of herpetic ulcers treated with one or other of these agents no difference could be found in the dendritic ulcer group (Fig. 1 ), but a trend emerged which suggested that F3T had some advantage over Ara-A in treating the less common but more severe amoeboid ulcers .
Not only are amoeboid ulcers less common than dendritic ulcers, they have often been treated with steroids before referral to an ophthalmologist, and many have associated stromal disease and uveitis. They constitute the most difficult therapeutic challenge for antiviral drugs used for ulcerative epithelial herpetic keratitis. Cases of this type are therefore more likely to show a difference in effectiveness between 2 highly active antiviral compounds than the less challenging cases of dendritic ulcer.
In the initial trial 102 patients were treated-87 with dendritic ulcers, 15 with amoeboid ulcers ulcers who consented to enter the study were included. All completed the course of treatment; 17 were treated with Ara-A and 13 with F3T.
The coded treatments were randomly allocated by the pharmacist within closely matched strata. The stratification was based on the features considered to be related to poor prognosis. These were: the size of the epithelial defect, whether the patient had been treated with steroids before coming to hospital. and whether or not the patient was atopic.
All patients were treated on an outpatient basis. The coded preparations consisted of either 3-3 % Ara-A ointment or 1% F3T drops, which were 418 (Mantell and Haenszell, 1959 ). An additional advantage is that it is not a parametric test and does not assume that the healing times follow a normal distribution. The distribution of healing times is set out in Fig. 4 , and clearly does not follow such a distribution.
A logrank analysis was performed on the data set out above. It indicates that the difference between the 2 treatment groups is likely to be significant In 6 patients the ulcers failed to heal. Four were treated with Ara-A and 2 with F3T. (Fig. 3) Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine phase occurred in a patient treated with Ara-A; a small epithelial defect developed 13 days after the initial ulcer had healed and 10 days after treatment had ceased.
Stromal disease progressed in 4 patients, all of whom had been treated with Ara-A: the epithelial defect failed to heal, and these cases were designated treatment failures.
The only manifestation of antiviral toxicity observed was punctate staining of the corneal epithelium with Bengal rose. This occurred in 3 patients treated with Ara-A and 4 treated with FjT; in one of the latter the epithelial defect failed to heal until the F3T was withdrawn (Fig. 3) .
Discussion
These results indicate that F3T is more effective than Ara-A in dealing with amoeboid ulcers. The superiority of F3T over Ara-A in the treatment of amoeboid ulcers, when no difference could be found in the dendritic ulcer group, reflects important differences between these 2 conditions. We were able to compare the patterns of these conditions during a period in which patients with dendritic or amoeboid ulcers were admitted to a treatment trial under the same protocol . In addition to the obvious difference in the size of the epithelial defect it was evident that, in comparison with dendritic ulcers, amoeboid ulcers occurred more often in patients who had been treated with topical steroids before coming to hospital and were more often complicated by stromal disease and uveitis. The duration of symptoms before coming to hospital was longer in the amoeboid group (Table 1) . No difference was evident with regard to sex or age of patients.
The apparent superiority of F3T over Ara-A in the treatment of such ulcers may be due to superior antiviral activity of F3T in the corneal epithelium, or it may be related to a more pronounced effect of this compound against stromal virus. The compounds may differ in their transepithelial absorption into the corneal stroma, or alternatively the large epithelial defect of amoeboid ulcers may allow greater stromal uptake of the more-water-soluble F5T than with the less-water-soluble Ara-A. The results of this trial have obvious implications for the clinician. They also indicate the need for stratifying, randomising, and ranking the nature of the epithelial defect and the extent of deep disease of the corneal stroma and uvea when planning clinical trials of antiherpetic agents.
Herpetic corneal ulceration has provided an important proving ground for antiviral compounds with clinical potential, the disease providing a wide range of therapeutic challenges. After debridement, ulcers, with their reduced viral load, provide the opportunity to demonstrate antiviral activity in lowpotency agents . Dendritic ulcers are appropriate for showing differences in more active compounds, and amoeboid ulcers provide the highest order of clinical challenge, capable of sorting out clinically important differences in activity between highly active compounds.
